Medicamentos modificadores en esclerosis múltiple: esquemas terapéuticos actuales

La esclerosis múltiple (EM) es una enfermedad crónica, autoinmune y neurodegenerativa; que tiene como principal característica la desmielinización de los axones en el sistema nervioso. Los medicamentos modificadores de la enfermedad (MME) logran retrasar la aparición de los síntomas y modificar parc...

Full description

Autores:
Ríos Martínez, María José
Arteaga, Anibal
Henao Pérez, Julieta
Vagner, Basilio
Castro Álvarez, John Fredy
Tipo de recurso:
Article of investigation
Fecha de publicación:
2020
Institución:
Universidad Cooperativa de Colombia
Repositorio:
Repositorio UCC
Idioma:
OAI Identifier:
oai:repository.ucc.edu.co:20.500.12494/33474
Acceso en línea:
https://hdl.handle.net/20.500.12494/33474
Palabra clave:
Esclerosis múltiple
Esclerosis múltiple crónica progresiva
Esclerosis múltiple recurrente-remitente
Tratamiento farmacológico
Inmunosupresores
Multiple sclerosis
Chronic progressive multiple sclerosis
Relapsing-remitting multiple sclerosis
Drug therapy
Immunosuppressive agents
Rights
openAccess
License
Atribución – No comercial – Sin Derivar
id COOPER2_a44de86b1975335b8c56f88282bf56db
oai_identifier_str oai:repository.ucc.edu.co:20.500.12494/33474
network_acronym_str COOPER2
network_name_str Repositorio UCC
repository_id_str
dc.title.spa.fl_str_mv Medicamentos modificadores en esclerosis múltiple: esquemas terapéuticos actuales
title Medicamentos modificadores en esclerosis múltiple: esquemas terapéuticos actuales
spellingShingle Medicamentos modificadores en esclerosis múltiple: esquemas terapéuticos actuales
Esclerosis múltiple
Esclerosis múltiple crónica progresiva
Esclerosis múltiple recurrente-remitente
Tratamiento farmacológico
Inmunosupresores
Multiple sclerosis
Chronic progressive multiple sclerosis
Relapsing-remitting multiple sclerosis
Drug therapy
Immunosuppressive agents
title_short Medicamentos modificadores en esclerosis múltiple: esquemas terapéuticos actuales
title_full Medicamentos modificadores en esclerosis múltiple: esquemas terapéuticos actuales
title_fullStr Medicamentos modificadores en esclerosis múltiple: esquemas terapéuticos actuales
title_full_unstemmed Medicamentos modificadores en esclerosis múltiple: esquemas terapéuticos actuales
title_sort Medicamentos modificadores en esclerosis múltiple: esquemas terapéuticos actuales
dc.creator.fl_str_mv Ríos Martínez, María José
Arteaga, Anibal
Henao Pérez, Julieta
Vagner, Basilio
Castro Álvarez, John Fredy
dc.contributor.author.none.fl_str_mv Ríos Martínez, María José
Arteaga, Anibal
Henao Pérez, Julieta
Vagner, Basilio
Castro Álvarez, John Fredy
dc.subject.spa.fl_str_mv Esclerosis múltiple
Esclerosis múltiple crónica progresiva
Esclerosis múltiple recurrente-remitente
Tratamiento farmacológico
Inmunosupresores
topic Esclerosis múltiple
Esclerosis múltiple crónica progresiva
Esclerosis múltiple recurrente-remitente
Tratamiento farmacológico
Inmunosupresores
Multiple sclerosis
Chronic progressive multiple sclerosis
Relapsing-remitting multiple sclerosis
Drug therapy
Immunosuppressive agents
dc.subject.other.spa.fl_str_mv Multiple sclerosis
Chronic progressive multiple sclerosis
Relapsing-remitting multiple sclerosis
Drug therapy
Immunosuppressive agents
description La esclerosis múltiple (EM) es una enfermedad crónica, autoinmune y neurodegenerativa; que tiene como principal característica la desmielinización de los axones en el sistema nervioso. Los medicamentos modificadores de la enfermedad (MME) logran retrasar la aparición de los síntomas y modificar parcialmente el progreso de la desmielinización y daño neuronal, resultando cada vez más complejo determinar un esquema terapéutico estandarizado según la condición particular de cada paciente. En este artículo se presenta una revisión actualizada de la evidencia clínica que ha llevado al uso de los esquemas terapéuticos en EM. La mayoría de los medicamentos aprobados actualmente son utilizados para la EM remitente-recurrente y se pueden dividir de acuerdo a la eficacia y seguridad. Los medicamentos de primera línea han mostrado una baja o moderada eficacia y alta seguridad; después de usar estos fármacos sin lograr una buena respuesta o ante una enfermedad avanzada se usan medicamentos de segunda y tercera línea que tienen una alta eficacia, pero son menos seguros, presentando mayores efectos secundarios y riesgos asociados para los pacientes. El ocrelizumab es el único fármaco aceptado para la EM primaria progresiva y el siponimod fue aprobado como una alternativa para la EM secundaria progresiva. El desarrollo de nuevos medicamentos y el seguimiento clínico de los ya aprobados permitirá establecer un mejor abordaje terapéutico logrando así mejorar la calidad de vida de cada paciente.
publishDate 2020
dc.date.issued.none.fl_str_mv 2020-08-31
dc.date.accessioned.none.fl_str_mv 2021-02-25T23:03:00Z
dc.date.available.none.fl_str_mv 2021-02-25T23:03:00Z
dc.type.none.fl_str_mv Artículos Científicos
dc.type.coar.none.fl_str_mv http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.coarversion.none.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.driver.none.fl_str_mv info:eu-repo/semantics/article
dc.type.version.none.fl_str_mv info:eu-repo/semantics/publishedVersion
format http://purl.org/coar/resource_type/c_2df8fbb1
status_str publishedVersion
dc.identifier.issn.spa.fl_str_mv 0718-4913
dc.identifier.uri.spa.fl_str_mv DOI: 10.5839/rcnp.2020.15.01.06
dc.identifier.uri.none.fl_str_mv https://hdl.handle.net/20.500.12494/33474
dc.identifier.bibliographicCitation.spa.fl_str_mv Ríos Martinez, M.J., Arteaga, A., Henao, J., Vagner , B., Castro-Álvarez, J.F. (2020). Medicamentos modificadores en esclerosis múltiple: esquemas terapéuticos actuales. Rev. Chil. Neuropsicol, 15(1), 32-37. DOI: 10.5839/rcnp.2020.15.01.06
identifier_str_mv 0718-4913
DOI: 10.5839/rcnp.2020.15.01.06
Ríos Martinez, M.J., Arteaga, A., Henao, J., Vagner , B., Castro-Álvarez, J.F. (2020). Medicamentos modificadores en esclerosis múltiple: esquemas terapéuticos actuales. Rev. Chil. Neuropsicol, 15(1), 32-37. DOI: 10.5839/rcnp.2020.15.01.06
url https://hdl.handle.net/20.500.12494/33474
dc.relation.isversionof.spa.fl_str_mv http://www.rcnp.cl/dinamicos/articulos/06_RIOS_RCNP_REVISION.pdf
dc.relation.ispartofjournal.spa.fl_str_mv Revista Chilena de Neuropsicología
dc.relation.references.spa.fl_str_mv Aharoni, R. (2013). The mechanism of action of glatiramer acetate in multiple sclerosis and beyond. Autoimmunity Reviews, 12(5), 543–553. https://doi.org/10.1016/j.autrev.2012.09.005
Brinkmann, V., Davis, M. D., Heise, C. E., Albert, R., Cottens, S., Hof, R., … Lynch, K. R. (2002). The immune modulator FTY720 targets sphingosine 1-phosphate receptors. Journal of Biological Chemistry, 277(24), 21453–21457. https://doi.org/10.1074/jbc.C200176200
Brown, J. W. L., Coles, A., Horakova, D., Havrdova, E., Izquierdo, G., Prat, A., … Robertson, N. (2019). Association of Initial DiseaseModifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA, 321(2), 175. https://doi.org/10.1001/jama.2018.20588
Calabresi, P. A., Kieseier, B. C., Arnold, D. L., Balcer, L. J., Boyko, A., Pelletier, J., … Seddighzadeh, A. (2014). Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis ( ADVANCE ): a randomised , phase 3 , double-blind study. The Lancet Neurology, 4422(14), 1–9. https://doi.org/10.1016/S1474-4422(14)70068-7
Calabresi, P. A., Radue, E., Goodin, D., Jeffery, D., Rammohan, K. W., Reder, A. T., … Lublin, F. D. (2014). Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebocontrolled, phase 3 trial. The Lancet Neurology, 13(6), 545–556. https://doi.org/10.1016/S1474-4422(14)70049-3
Caliceti, P., & Veronese, F. (2003). Pharmacokinetic and biodistribution properties of poly(ethylene glycol)–protein conjugates. Advanced Drug Delivery Reviews, 55(10), 1261–1277. https://doi.org/10.1016/S0169-409X(03)00108-X
Cohen, J. A., Barkhof, F., Comi, G., Hartung, H., Khatri, B. O., Montalban, X., … Kappos, L. (2010). Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis. New England Journal of Medicine, 362(5), 402–415. https://doi.org/10.1056/NEJMoa0907839
Cohen, J. A., Coles, A. J., Arnold, D. L., Confavreux, C., Fox, E. J., Hartung, H.-P., … Compston, D. A. S. (2012). Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. The Lancet, 380(9856), 1819–1828. https://doi.org/10.1016/S0140-6736(12)61769-3
Coles, A. J., Cox, A., Page, E., Jones, J., Trip, S. A., Deans, J., … Compston, D. A. (2006). The window of therapeutic opportunity in multiple sclerosis. Journal of Neurology, 253(1), 98–108. https://doi.org/10.1007/s00415-005-0934-5
Coles, A. J., Twyman, C. L., Arnold, D. L., Cohen, J. A., Confavreux, C., Fox, E. J., … Compston, D. A. S. (2012). Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. The Lancet, 380(9856), 1829–1839. https://doi.org/10.1016/S0140-6736(12)61768-1
Comi, G., Filippi, M., & Wolinsky, J. S. (2001). European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Annals of Neurology, 49(3), 290–297. https://doi.org/10.1002/ana.64
Compston, A., Confavreux, C., Lassmann, H., McDonald, I., Miller, D., Noseworthy, J., … Wekerle, H. (2013). McAlpine’s Multiple Sclerosis (Cuarta Ed.). Philadelphia: Elsevier Inc.
Confavreux, C., O’Connor, P., Comi, G., Freedman, M. S., Miller, A. E., Olsson, T. P., … Kappos, L. (2014). Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): A randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Neurology, 13(3), 247–256. https://doi.org/10.1016/S1474- 4422(13)70308-9
Crabtree-Hartman, E. (2018). Advanced Symptom Management in Multiple Sclerosis. Neurologic Clinics, 36(1), 197–218. https://doi.org/10.1016/j.ncl.2017.08.015
De Angelis, F., Brownlee, W. J., Chard, D. T., & Trip, S. A. (2019). New MS diagnostic criteria in practice. Practical Neurology, 19(1), 64–67. https://doi.org/10.1136/practneurol-2018-001945
De Angelis, F., John, N. A., & Brownlee, W. J. (2018). Disease-modifying therapies for multiple sclerosis. BMJ, 65(5), k4674. https://doi.org/10.1136/bmj.k4674
Ebers, G. C. (1998). Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. The Lancet, 352(9139), 1498–1504. https://doi.org/10.1016/S0140- 6736(98)03334-0
Fernández, Ó., Tintoré, M., Saiz, A., Calles-hernández, M. C., Comabella, M., Ramió-torrentà, L., … Rodríguez-antigüedad, A. (2018). Revisión de las novedades del Congreso ECTRIMS 2017 , presentadas en la X Reunión Post-ECTRIMS ( II ). 67(Ii), 50–62.
Filippi, M., Bar-Or, A., Piehl, F., Preziosa, P., Solari, A., Vukusic, S., & Rocca, M. A. (2018). Multiple sclerosis. Nature Reviews Disease Primers, 4(1), 43. https://doi.org/10.1038/s41572-018-0041-4
Fox, R. J., Miller, D. H., Phillips, J. T., Hutchinson, M., Havrdova, E., Kita, M., … Dawson, K. T. (2012). Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis. New England Journal of Medicine, 367(12), 1087–1097. https://doi.org/10.1056/NEJMoa1206328
Francis, G., Kappos, L., O’Connor, P., Collins, W., Tang, D., Mercier, F., & Cohen, J. (2014). Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy. Multiple Sclerosis Journal, 20(4), 471–480. https://doi.org/10.1177/1352458513500551
Furber, K. L., Van Agten, M., Evans, C., Haddadi, A., Doucette, J. R., & Nazarali, A. J. (2017). Advances in the treatment of relapsingremitting multiple sclerosis: the role of pegylated interferon beta1a. Degenerative Neurological and Neuromuscular Disease, Volume 7(2), 47–60. https://doi.org/10.2147/DNND.S71986
Gergely, P., Nuesslein-Hildesheim, B., Guerini, D., Brinkmann, V., Traebert, M., Bruns, C., … Wallström, E. (2012). The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. British Journal of Pharmacology, 167(5), 1035–1047. https://doi.org/10.1111/j.1476-5381.2012.02061.x
Geurts, J. J. G., Bö, L., Pouwels, P. J. W., Castelijns, J. A., Polman, C. H., & Barkhof, F. (2005). Cortical lesions in multiple sclerosis: Combined postmortem MR imaging and histopathology. American Journal of Neuroradiology, 26(3), 572–577. https://doi.org/26/3/572 [pii]
Giovannoni, G. (2016). Multiple sclerosis should be treated using a stepdown strategy rather than a step-up strategy–YES. Multiple Sclerosis Journal, 22(11), 1397–1400. https://doi.org/10.1177/1352458516650737
Gold, R., Kappos, L., Arnold, D. L., Bar-Or, A., Giovannoni, G., Selmaj, K., … Dawson, K. T. (2012). Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis. New England Journal of Medicine, 367(12), 1098–1107. https://doi.org/10.1056/NEJMoa1114287
Hale, G., Rye, P. D., Warford, A., Lauder, I., & Brito-Babapulle, A. (1993). The glycosylphosphatidylinositol-anchored lymphocyte antigen CDw52 is associated with the epididymal maturation of human spermatozoa. Journal of Reproductive Immunology, 23(2), 189–205. https://doi.org/10.1016/0165-0378(93)90007-5
Hauser, S. L., Bar-Or, A., Comi, G., Giovannoni, G., Hartung, H.-P., Hemmer, B., … Kappos, L. (2017). Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. New England Journal of Medicine, 376(3), 221–234. https://doi.org/10.1056/NEJMoa1601277
Ingwersen, J., Aktas, O., & Hartung, H.-P. (2016). Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis. Neurotherapeutics, 13(1), 47–57. https://doi.org/10.1007/s13311-015-0412-4
Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. M., … Whitham, R. H. (1996). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Annals of Neurology, 39(3), 285–294. https://doi.org/10.1002/ana.410390304
Jakimovski, D., Kolb, C., Ramanathan, M., Zivadinov, R., & WeinstockGuttman, B. (2018). Interferon β for Multiple Sclerosis. Cold Spring Harbor Perspectives in Medicine, 8(11), a032003. https://doi.org/10.1101/cshperspect.a032003
Johnson, K. P., Brooks, B. R., Cohen, J. A., Ford, C. C., Goldstein, J., Lisak, R. P., … Wolinsky, J. S. (1995). Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebocontrolled trial. Neurology, 45(7), 1268–1276. https://doi.org/10.1212/WNL.45.7.1268
Juanatey García, A., Blanco García, L., & Téllez Lara, N. (2018). Ocrelizumab: eficacia y seguridad en la esclerosis múltiple. Revista de Neurología, 66(12), 423. https://doi.org/10.33588/rn.6612.2018132
Kappos, L., Bar-Or, A., Cree, B. A. C., Fox, R. J., Giovannoni, G., Gold, R., … Ziemssen, T. (2018). Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. The Lancet, 391(10127), 1263–1273. https://doi.org/10.1016/S0140-6736(18)30475-6
Kappos, L., Radue, E.-W., O’Connor, P., Polman, C., Hohlfeld, R., Calabresi, P., … Burtin, P. (2010). A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis. New England Journal of Medicine, 362(5), 387–401. https://doi.org/10.1056/NEJMoa0909494
Kubsik-Gidlewska, A. M., Klimkiewicz, P., Klimkiewicz, R., Janczewska, K., & Woldañska-Okoñska, M. (2017). Rehabilitation in multiple sclerosis. Advances in Clinical and Experimental Medicine, 26(4), 709– 715. https://doi.org/10.17219/acem/62329
Linker, R. A., Lee, D. H., Ryan, S., Van Dam, A. M., Conrad, R., Bista, P., … Gold, R. (2011). Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain, 134(3), 678–692. https://doi.org/10.1093/brain/awq386
Lucchetta, R. C., Tonin, F. S., Borba, H. H. L., Leonart, L. P., Ferreira, V. L., Bonetti, A. F., … Wiens, A. (2018). Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis: A Network MetaAnalysis. CNS Drugs, 32(9), 813–826. https://doi.org/10.1007/s40263-018-0541-5
Lucchinetti, C., Brück, W., Parisi, J., Scheithauer, B., Rodriguez, M., & Lassmann, H. (2000). Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Annals of neurology, 47(6), 707–717. https://doi.org/10.1002/1531- 8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q
Lundy, S. K., Wu, Q., Wang, Q., Dowling, C. A., Taitano, S. H., Mao, G., & Mao-Draayer, Y. (2016). Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets. Neurology - Neuroimmunology Neuroinflammation, 3(2), e211. https://doi.org/10.1212/NXI.0000000000000211
Montalban, X., Gold, R., Thompson, A. J., Otero-Romero, S., Amato, M. P., Chandraratna, D., … Zipp, F. (2018). ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. European Journal of Neurology, 25(2), 215–237. https://doi.org/10.1111/ene.13536
Montalban, Xavier, Hauser, S. L., Kappos, L., Arnold, D. L., Bar-Or, A., Comi, G., … Wolinsky, J. S. (2017). Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. New England Journal of Medicine, 376(3), 209–220. https://doi.org/10.1056/NEJMoa1606468
Naismith, R. T. (2016). Multiple sclerosis should be treated using a step-down strategy rather than a step-up strategy–NO. Multiple Sclerosis Journal, 22(11), 1400–1402. https://doi.org/10.1177/1352458516644676
O’Connor, P., Wolinsky, J. S., Confavreux, C., Comi, G., Kappos, L., Olsson, T. P., … Freedman, M. S. (2011). Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis. New England Journal of Medicine, 365(14), 1293–1303. https://doi.org/10.1056/NEJMoa1014656
Okuda, D. T., Siva, A., Kantarci, O., Inglese, M., Katz, I., Tutuncu, M., … Lebrun, C. (2014). Radiologically Isolated Syndrome: 5-Year Risk for an Initial Clinical Event. PLoS ONE, 9(3), e90509. https://doi.org/10.1371/journal.pone.0090509
Ontaneda, D., Tallantyre, E., Kalincik, T., Planchon, S. M., & Evangelou, N. (2019). Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis. The Lancet Neurology, 18(10), 973–980. https://doi.org/10.1016/S1474- 4422(19)30151-6
Pan, S., Gray, N. S., Gao, W., Mi, Y., Fan, Y., Wang, X., … NuessleinHildesheim, B. (2013). Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator. ACS Medicinal Chemistry Letters, 4(3), 333–337. https://doi.org/10.1021/ml300396r
Paty, D. W., & Li, D. K. B. (1993). Interferon beta-1b is effective in relapsingremitting multiple sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology, 43(4), 662–667. https://doi.org/10.1212/WNL.43.4.662
Polman, C. H., O’Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., … Sandrock, A. W. (2006). A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis. New England Journal of Medicine, 354(9), 899–910. https://doi.org/10.1056/NEJMoa044397
Przybek, J., Gniatkowska, I., Mirowska-Guzel, D., & Członkowska, A. (2015). Evolution of diagnostic criteria for multiple sclerosis. Neurologia i Neurochirurgia Polska, 49(5), 313–321. https://doi.org/10.1016/j.pjnns.2015.07.006
Reff, M. E., Carner, K., Chambers, K. S., Chinn, P. C., Leonard, J. E., Raab, R., … Anderson, D. R. (1994). Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood, 83(2), 435–445.
Rückemann, K., Fairbanks, L. D., Carrey, E. A., Hawrylowicz, C. M., Richards, D. F., Kirschbaum, B., & Simmonds, H. A. (1998). Leflunomide Inhibits Pyrimidine de Novo Synthesis in Mitogenstimulated T-lymphocytes from Healthy Humans. Journal of Biological Chemistry, 273(34), 21682–21691. https://doi.org/10.1074/jbc.273.34.21682
Scannevin, R. H., Chollate, S., Jung, M. -y., Shackett, M., Patel, H., Bista, P., … Rhodes, K. J. (2012). Fumarates Promote Cytoprotection of Central Nervous System Cells against Oxidative Stress via the Nuclear Factor (Erythroid-Derived 2)-Like 2 Pathway. Journal of Pharmacology and Experimental Therapeutics, 341(1), 274–284. https://doi.org/10.1124/jpet.111.190132
Stashenko, P., Nadler, L. E. E. M., Hardy, R., & Schlossman, S. F. (1980). Characterization of a human B lymphocyte-specific antigen. The Journal of Immunology, 125(4), 1678–1685.
The IFNB Multiple Sclerosis Study Group. (1993). Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebocontrolled trial. The IFNB Multiple Sclerosis Study Group. Neurology, 43(4), 655–661.
Thompson, A. J., Banwell, B. L., Barkhof, F., Carroll, W. M., Coetzee, T., Comi, G., … Cohen, J. A. (2018). Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. The Lancet Neurology, 17(2), 162–173. https://doi.org/10.1016/S1474-4422(17)30470- 2
Tolley, K., Hutchinson, M., You, X., Wang, P., Sperling, B., Taneja, A., … Kinter, E. (2015). A network meta-analysis of efficacy and evaluation of safety of subcutaneous pegylated interferon beta-1a versus other injectable therapies for the treatment of relapsingremitting multiple sclerosis. PLoS ONE, 10(6), 1–21. https://doi.org/10.1371/journal.pone.0127960
U.S Food and Drug Administration (FDA). (1993). BETASERON. Recuperado el 19 de febrero de 2019, de https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/1 03471s0000TOC.cfm
U.S Food and Drug Administration (FDA). (1996a). AVONEX. Recuperado el 19 de febrero de 2019, de https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/1036 28s0000TOC.cfm
U.S Food and Drug Administration (FDA). (1996b). COPAXONE. Recuperado el 19 de febrero de 2019, de https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?ev ent=overview.process&ApplNo=020622
U.S Food and Drug Administration (FDA). (2001). ALEMTUZUMAB. Recuperado el 19 de febrero de 2019, de https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?ev ent=overview.process&ApplNo=103948
U.S Food and Drug Administration (FDA). (2004). TYSABRI. Recuperado el 19 de febrero de 2019, de https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/12 5104s000_natalizumab.cfm
U.S Food and Drug Administration (FDA). (2010). GYLENIA. Recuperado el 19 de febrero de 2019, de https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/02 2527Orig1s000TOC.cfm
U.S Food and Drug Administration (FDA). (2012). AUBAGIO. Recuperado el 19 de febrero de 2019, de https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/20 2992Orig1s000TOC.cfm
U.S Food and Drug Administration (FDA). (2013). TECFIDERA. Recuperado el 19 de febrero de 2019, de https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/20 4063orig1s000toc.cfm
U.S Food and Drug Administration (FDA). (2017). OCREVUS. Recuperado el 19 de febrero de 2019, de https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/76 1053Orig1s000TOC.cfm
Vargas, D. L., & Tyor, W. R. (2017). Update on disease-modifying therapies for multiple sclerosis. Journal of Investigative Medicine, 65(5), 883– 891. https://doi.org/10.1136/jim-2016-000339
Weideman, A. M., Tapia-Maltos, M. A., Johnson, K., Greenwood, M., & Bielekova, B. (2017). Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments. Frontiers in Neurology, 8(NOV), 1–12. https://doi.org/10.3389/fneur.2017.00577
Xia, M. -Q, Tone, M., Packman, L., Hale, G., & Waldmann, H. (1991). Characterization of the CAMPATH-1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone. European Journal of Immunology, 21(7), 1677– 1684. https://doi.org/10.1002/eji.1830210714
Yednock, T. A., Cannon, C., Fritz, L. C., Sanchez-Madrid, F., Steinman, L., & Karin, N. (1992). Prevention of experimental autoimmune encephalomyelitis by antibodies against α4βl integrin. Nature, 356(6364), 63–66. https://doi.org/10.1038/356063a0.
dc.rights.license.none.fl_str_mv Atribución – No comercial – Sin Derivar
dc.rights.accessrights.none.fl_str_mv info:eu-repo/semantics/openAccess
dc.rights.coar.none.fl_str_mv http://purl.org/coar/access_right/c_abf2
rights_invalid_str_mv Atribución – No comercial – Sin Derivar
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.extent.spa.fl_str_mv p. 32-37
dc.coverage.temporal.spa.fl_str_mv Vol. 15 No.1
dc.publisher.spa.fl_str_mv Francisco Ceric,
Universidad Cooperativa de Colombia, Facultad de Ciencias de la Salud, Medicina, Medellín y Envigado
dc.publisher.program.spa.fl_str_mv Medicina
dc.publisher.place.spa.fl_str_mv Medellín
institution Universidad Cooperativa de Colombia
bitstream.url.fl_str_mv https://repository.ucc.edu.co/bitstreams/4da7324d-808a-494d-a89d-8a41497a40e7/download
https://repository.ucc.edu.co/bitstreams/4542d997-51d1-45d1-bc8e-2c9981c9588c/download
https://repository.ucc.edu.co/bitstreams/cfbd982a-b2e3-44ac-8e1e-d701ee1fe32c/download
https://repository.ucc.edu.co/bitstreams/3f3816cd-eafa-4fe0-8de4-fdc2637d2b30/download
bitstream.checksum.fl_str_mv 6404aafd01cfc8df5025809ac0f2de9d
3bce4f7ab09dfc588f126e1e36e98a45
7409c6bae8b75db76e16be540d4a5af5
eddb4ee08f2ef728fb5d03eb47533792
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Institucional Universidad Cooperativa de Colombia
repository.mail.fl_str_mv bdigital@metabiblioteca.com
_version_ 1811565508669997056
spelling Ríos Martínez, María JoséArteaga, AnibalHenao Pérez, JulietaVagner, BasilioCastro Álvarez, John FredyVol. 15 No.12021-02-25T23:03:00Z2021-02-25T23:03:00Z2020-08-310718-4913DOI: 10.5839/rcnp.2020.15.01.06https://hdl.handle.net/20.500.12494/33474Ríos Martinez, M.J., Arteaga, A., Henao, J., Vagner , B., Castro-Álvarez, J.F. (2020). Medicamentos modificadores en esclerosis múltiple: esquemas terapéuticos actuales. Rev. Chil. Neuropsicol, 15(1), 32-37. DOI: 10.5839/rcnp.2020.15.01.06La esclerosis múltiple (EM) es una enfermedad crónica, autoinmune y neurodegenerativa; que tiene como principal característica la desmielinización de los axones en el sistema nervioso. Los medicamentos modificadores de la enfermedad (MME) logran retrasar la aparición de los síntomas y modificar parcialmente el progreso de la desmielinización y daño neuronal, resultando cada vez más complejo determinar un esquema terapéutico estandarizado según la condición particular de cada paciente. En este artículo se presenta una revisión actualizada de la evidencia clínica que ha llevado al uso de los esquemas terapéuticos en EM. La mayoría de los medicamentos aprobados actualmente son utilizados para la EM remitente-recurrente y se pueden dividir de acuerdo a la eficacia y seguridad. Los medicamentos de primera línea han mostrado una baja o moderada eficacia y alta seguridad; después de usar estos fármacos sin lograr una buena respuesta o ante una enfermedad avanzada se usan medicamentos de segunda y tercera línea que tienen una alta eficacia, pero son menos seguros, presentando mayores efectos secundarios y riesgos asociados para los pacientes. El ocrelizumab es el único fármaco aceptado para la EM primaria progresiva y el siponimod fue aprobado como una alternativa para la EM secundaria progresiva. El desarrollo de nuevos medicamentos y el seguimiento clínico de los ya aprobados permitirá establecer un mejor abordaje terapéutico logrando así mejorar la calidad de vida de cada paciente.Multiple sclerosis (MS) is a chronic, autoimmune and neurodegenerative disease; whose main characteristic is the demyelination of axons in the nervous system. Disease-modifying drugs (DMD) can delay the onset of symptoms and partially modify the progression of demyelination and neuronal damage, making it increasingly complex to determine a standardized therapeutic scheme that is individualized to each patient. This article presents an updated review on the clinical evidence that has led to the use of current therapeutic schemes in MS with focus on DMD. Current medications in treating relapsing-remitting MS can be divided according to efficacy and safety. First-line drugs have shown low or moderate efficacy and high safety. Second- and third-line drugs are used after a poor response or in cases of advanced disease. These drugs are highly effective, but less safe, presenting greater side effects and associated risks for patients. Ocrelizumab is the only accepted drug for primary progressive MS and siponimod is accepted as an alternative for secondary progressive MS. The development of new medications and the clinical follow-up of those already approved will allow establishing a better therapeutic approach, thus improving the quality of life of each patient.Introducción. -- Curso de la esclerosis múltiple. -- Principales medicamentos. -- Escalamiento terapéutico o terapia de inducción. -- Conclusión.https://scienti.minciencias.gov.co/cvlac/visualizador/generarCurriculoCv.do?cod_rh=0000088471https://scienti.minciencias.gov.co/cvlac/visualizador/generarCurriculoCv.do?cod_rh=0000290289https://scienti.minciencias.gov.co/cvlac/visualizador/generarCurriculoCv.do?cod_rh=0000063498https://scienti.minciencias.gov.co/cvlac/visualizador/generarCurriculoCv.do?cod_rh=0001658240https://orcid.org/0000-0002-6612-1169https://orcid.org/0000-0002-9380-116Xhttps://orcid.org/0000-0002-7957-7923https://orcid.org/0000-0002-9049-0271https://scienti.minciencias.gov.co/gruplac/jsp/visualiza/visualizagr.jsp?nro=00000000005562https://scienti.minciencias.gov.co/gruplac/jsp/visualiza/visualizagr.jsp?nro=00000000011355mariajoseriosmartinez@hotmail.comanibal.arteaga@uniremington.edu.cojulieta.henaop@campusucc.edu.cobasilio_vagner@hotmail.comjohn.castro@uniremington.edu.co.https://scholar.google.es/citations?user=kfzY1SUAAAAJ&hl=eshttps://scholar.google.com/citations?user=torM76QAAAAJ&hl=enhttps://scholar.google.es/citations?user=-2VEGSIAAAAJ&hl=eshttps://scholar.google.com/citations?user=MJNLbzcAAAAJ&hl=esp. 32-37Francisco Ceric,Universidad Cooperativa de Colombia, Facultad de Ciencias de la Salud, Medicina, Medellín y EnvigadoMedicinaMedellínhttp://www.rcnp.cl/dinamicos/articulos/06_RIOS_RCNP_REVISION.pdfRevista Chilena de NeuropsicologíaAharoni, R. (2013). The mechanism of action of glatiramer acetate in multiple sclerosis and beyond. Autoimmunity Reviews, 12(5), 543–553. https://doi.org/10.1016/j.autrev.2012.09.005Brinkmann, V., Davis, M. D., Heise, C. E., Albert, R., Cottens, S., Hof, R., … Lynch, K. R. (2002). The immune modulator FTY720 targets sphingosine 1-phosphate receptors. Journal of Biological Chemistry, 277(24), 21453–21457. https://doi.org/10.1074/jbc.C200176200Brown, J. W. L., Coles, A., Horakova, D., Havrdova, E., Izquierdo, G., Prat, A., … Robertson, N. (2019). Association of Initial DiseaseModifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA, 321(2), 175. https://doi.org/10.1001/jama.2018.20588Calabresi, P. A., Kieseier, B. C., Arnold, D. L., Balcer, L. J., Boyko, A., Pelletier, J., … Seddighzadeh, A. (2014). Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis ( ADVANCE ): a randomised , phase 3 , double-blind study. The Lancet Neurology, 4422(14), 1–9. https://doi.org/10.1016/S1474-4422(14)70068-7Calabresi, P. A., Radue, E., Goodin, D., Jeffery, D., Rammohan, K. W., Reder, A. T., … Lublin, F. D. (2014). Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebocontrolled, phase 3 trial. The Lancet Neurology, 13(6), 545–556. https://doi.org/10.1016/S1474-4422(14)70049-3Caliceti, P., & Veronese, F. (2003). Pharmacokinetic and biodistribution properties of poly(ethylene glycol)–protein conjugates. Advanced Drug Delivery Reviews, 55(10), 1261–1277. https://doi.org/10.1016/S0169-409X(03)00108-XCohen, J. A., Barkhof, F., Comi, G., Hartung, H., Khatri, B. O., Montalban, X., … Kappos, L. (2010). Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis. New England Journal of Medicine, 362(5), 402–415. https://doi.org/10.1056/NEJMoa0907839Cohen, J. A., Coles, A. J., Arnold, D. L., Confavreux, C., Fox, E. J., Hartung, H.-P., … Compston, D. A. S. (2012). Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. The Lancet, 380(9856), 1819–1828. https://doi.org/10.1016/S0140-6736(12)61769-3Coles, A. J., Cox, A., Page, E., Jones, J., Trip, S. A., Deans, J., … Compston, D. A. (2006). The window of therapeutic opportunity in multiple sclerosis. Journal of Neurology, 253(1), 98–108. https://doi.org/10.1007/s00415-005-0934-5Coles, A. J., Twyman, C. L., Arnold, D. L., Cohen, J. A., Confavreux, C., Fox, E. J., … Compston, D. A. S. (2012). Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. The Lancet, 380(9856), 1829–1839. https://doi.org/10.1016/S0140-6736(12)61768-1Comi, G., Filippi, M., & Wolinsky, J. S. (2001). European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Annals of Neurology, 49(3), 290–297. https://doi.org/10.1002/ana.64Compston, A., Confavreux, C., Lassmann, H., McDonald, I., Miller, D., Noseworthy, J., … Wekerle, H. (2013). McAlpine’s Multiple Sclerosis (Cuarta Ed.). Philadelphia: Elsevier Inc.Confavreux, C., O’Connor, P., Comi, G., Freedman, M. S., Miller, A. E., Olsson, T. P., … Kappos, L. (2014). Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): A randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Neurology, 13(3), 247–256. https://doi.org/10.1016/S1474- 4422(13)70308-9Crabtree-Hartman, E. (2018). Advanced Symptom Management in Multiple Sclerosis. Neurologic Clinics, 36(1), 197–218. https://doi.org/10.1016/j.ncl.2017.08.015De Angelis, F., Brownlee, W. J., Chard, D. T., & Trip, S. A. (2019). New MS diagnostic criteria in practice. Practical Neurology, 19(1), 64–67. https://doi.org/10.1136/practneurol-2018-001945De Angelis, F., John, N. A., & Brownlee, W. J. (2018). Disease-modifying therapies for multiple sclerosis. BMJ, 65(5), k4674. https://doi.org/10.1136/bmj.k4674Ebers, G. C. (1998). Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. The Lancet, 352(9139), 1498–1504. https://doi.org/10.1016/S0140- 6736(98)03334-0Fernández, Ó., Tintoré, M., Saiz, A., Calles-hernández, M. C., Comabella, M., Ramió-torrentà, L., … Rodríguez-antigüedad, A. (2018). Revisión de las novedades del Congreso ECTRIMS 2017 , presentadas en la X Reunión Post-ECTRIMS ( II ). 67(Ii), 50–62.Filippi, M., Bar-Or, A., Piehl, F., Preziosa, P., Solari, A., Vukusic, S., & Rocca, M. A. (2018). Multiple sclerosis. Nature Reviews Disease Primers, 4(1), 43. https://doi.org/10.1038/s41572-018-0041-4Fox, R. J., Miller, D. H., Phillips, J. T., Hutchinson, M., Havrdova, E., Kita, M., … Dawson, K. T. (2012). Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis. New England Journal of Medicine, 367(12), 1087–1097. https://doi.org/10.1056/NEJMoa1206328Francis, G., Kappos, L., O’Connor, P., Collins, W., Tang, D., Mercier, F., & Cohen, J. (2014). Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy. Multiple Sclerosis Journal, 20(4), 471–480. https://doi.org/10.1177/1352458513500551Furber, K. L., Van Agten, M., Evans, C., Haddadi, A., Doucette, J. R., & Nazarali, A. J. (2017). Advances in the treatment of relapsingremitting multiple sclerosis: the role of pegylated interferon beta1a. Degenerative Neurological and Neuromuscular Disease, Volume 7(2), 47–60. https://doi.org/10.2147/DNND.S71986Gergely, P., Nuesslein-Hildesheim, B., Guerini, D., Brinkmann, V., Traebert, M., Bruns, C., … Wallström, E. (2012). The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. British Journal of Pharmacology, 167(5), 1035–1047. https://doi.org/10.1111/j.1476-5381.2012.02061.xGeurts, J. J. G., Bö, L., Pouwels, P. J. W., Castelijns, J. A., Polman, C. H., & Barkhof, F. (2005). Cortical lesions in multiple sclerosis: Combined postmortem MR imaging and histopathology. American Journal of Neuroradiology, 26(3), 572–577. https://doi.org/26/3/572 [pii]Giovannoni, G. (2016). Multiple sclerosis should be treated using a stepdown strategy rather than a step-up strategy–YES. Multiple Sclerosis Journal, 22(11), 1397–1400. https://doi.org/10.1177/1352458516650737Gold, R., Kappos, L., Arnold, D. L., Bar-Or, A., Giovannoni, G., Selmaj, K., … Dawson, K. T. (2012). Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis. New England Journal of Medicine, 367(12), 1098–1107. https://doi.org/10.1056/NEJMoa1114287Hale, G., Rye, P. D., Warford, A., Lauder, I., & Brito-Babapulle, A. (1993). The glycosylphosphatidylinositol-anchored lymphocyte antigen CDw52 is associated with the epididymal maturation of human spermatozoa. Journal of Reproductive Immunology, 23(2), 189–205. https://doi.org/10.1016/0165-0378(93)90007-5Hauser, S. L., Bar-Or, A., Comi, G., Giovannoni, G., Hartung, H.-P., Hemmer, B., … Kappos, L. (2017). Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. New England Journal of Medicine, 376(3), 221–234. https://doi.org/10.1056/NEJMoa1601277Ingwersen, J., Aktas, O., & Hartung, H.-P. (2016). Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis. Neurotherapeutics, 13(1), 47–57. https://doi.org/10.1007/s13311-015-0412-4Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. M., … Whitham, R. H. (1996). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Annals of Neurology, 39(3), 285–294. https://doi.org/10.1002/ana.410390304Jakimovski, D., Kolb, C., Ramanathan, M., Zivadinov, R., & WeinstockGuttman, B. (2018). Interferon β for Multiple Sclerosis. Cold Spring Harbor Perspectives in Medicine, 8(11), a032003. https://doi.org/10.1101/cshperspect.a032003Johnson, K. P., Brooks, B. R., Cohen, J. A., Ford, C. C., Goldstein, J., Lisak, R. P., … Wolinsky, J. S. (1995). Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebocontrolled trial. Neurology, 45(7), 1268–1276. https://doi.org/10.1212/WNL.45.7.1268Juanatey García, A., Blanco García, L., & Téllez Lara, N. (2018). Ocrelizumab: eficacia y seguridad en la esclerosis múltiple. Revista de Neurología, 66(12), 423. https://doi.org/10.33588/rn.6612.2018132Kappos, L., Bar-Or, A., Cree, B. A. C., Fox, R. J., Giovannoni, G., Gold, R., … Ziemssen, T. (2018). Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. The Lancet, 391(10127), 1263–1273. https://doi.org/10.1016/S0140-6736(18)30475-6Kappos, L., Radue, E.-W., O’Connor, P., Polman, C., Hohlfeld, R., Calabresi, P., … Burtin, P. (2010). A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis. New England Journal of Medicine, 362(5), 387–401. https://doi.org/10.1056/NEJMoa0909494Kubsik-Gidlewska, A. M., Klimkiewicz, P., Klimkiewicz, R., Janczewska, K., & Woldañska-Okoñska, M. (2017). Rehabilitation in multiple sclerosis. Advances in Clinical and Experimental Medicine, 26(4), 709– 715. https://doi.org/10.17219/acem/62329Linker, R. A., Lee, D. H., Ryan, S., Van Dam, A. M., Conrad, R., Bista, P., … Gold, R. (2011). Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain, 134(3), 678–692. https://doi.org/10.1093/brain/awq386Lucchetta, R. C., Tonin, F. S., Borba, H. H. L., Leonart, L. P., Ferreira, V. L., Bonetti, A. F., … Wiens, A. (2018). Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis: A Network MetaAnalysis. CNS Drugs, 32(9), 813–826. https://doi.org/10.1007/s40263-018-0541-5Lucchinetti, C., Brück, W., Parisi, J., Scheithauer, B., Rodriguez, M., & Lassmann, H. (2000). Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Annals of neurology, 47(6), 707–717. https://doi.org/10.1002/1531- 8249(200006)47:6<707::AID-ANA3>3.0.CO;2-QLundy, S. K., Wu, Q., Wang, Q., Dowling, C. A., Taitano, S. H., Mao, G., & Mao-Draayer, Y. (2016). Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets. Neurology - Neuroimmunology Neuroinflammation, 3(2), e211. https://doi.org/10.1212/NXI.0000000000000211Montalban, X., Gold, R., Thompson, A. J., Otero-Romero, S., Amato, M. P., Chandraratna, D., … Zipp, F. (2018). ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. European Journal of Neurology, 25(2), 215–237. https://doi.org/10.1111/ene.13536Montalban, Xavier, Hauser, S. L., Kappos, L., Arnold, D. L., Bar-Or, A., Comi, G., … Wolinsky, J. S. (2017). Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. New England Journal of Medicine, 376(3), 209–220. https://doi.org/10.1056/NEJMoa1606468Naismith, R. T. (2016). Multiple sclerosis should be treated using a step-down strategy rather than a step-up strategy–NO. Multiple Sclerosis Journal, 22(11), 1400–1402. https://doi.org/10.1177/1352458516644676O’Connor, P., Wolinsky, J. S., Confavreux, C., Comi, G., Kappos, L., Olsson, T. P., … Freedman, M. S. (2011). Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis. New England Journal of Medicine, 365(14), 1293–1303. https://doi.org/10.1056/NEJMoa1014656Okuda, D. T., Siva, A., Kantarci, O., Inglese, M., Katz, I., Tutuncu, M., … Lebrun, C. (2014). Radiologically Isolated Syndrome: 5-Year Risk for an Initial Clinical Event. PLoS ONE, 9(3), e90509. https://doi.org/10.1371/journal.pone.0090509Ontaneda, D., Tallantyre, E., Kalincik, T., Planchon, S. M., & Evangelou, N. (2019). Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis. The Lancet Neurology, 18(10), 973–980. https://doi.org/10.1016/S1474- 4422(19)30151-6Pan, S., Gray, N. S., Gao, W., Mi, Y., Fan, Y., Wang, X., … NuessleinHildesheim, B. (2013). Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator. ACS Medicinal Chemistry Letters, 4(3), 333–337. https://doi.org/10.1021/ml300396rPaty, D. W., & Li, D. K. B. (1993). Interferon beta-1b is effective in relapsingremitting multiple sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology, 43(4), 662–667. https://doi.org/10.1212/WNL.43.4.662Polman, C. H., O’Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., … Sandrock, A. W. (2006). A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis. New England Journal of Medicine, 354(9), 899–910. https://doi.org/10.1056/NEJMoa044397Przybek, J., Gniatkowska, I., Mirowska-Guzel, D., & Członkowska, A. (2015). Evolution of diagnostic criteria for multiple sclerosis. Neurologia i Neurochirurgia Polska, 49(5), 313–321. https://doi.org/10.1016/j.pjnns.2015.07.006Reff, M. E., Carner, K., Chambers, K. S., Chinn, P. C., Leonard, J. E., Raab, R., … Anderson, D. R. (1994). Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood, 83(2), 435–445.Rückemann, K., Fairbanks, L. D., Carrey, E. A., Hawrylowicz, C. M., Richards, D. F., Kirschbaum, B., & Simmonds, H. A. (1998). Leflunomide Inhibits Pyrimidine de Novo Synthesis in Mitogenstimulated T-lymphocytes from Healthy Humans. Journal of Biological Chemistry, 273(34), 21682–21691. https://doi.org/10.1074/jbc.273.34.21682Scannevin, R. H., Chollate, S., Jung, M. -y., Shackett, M., Patel, H., Bista, P., … Rhodes, K. J. (2012). Fumarates Promote Cytoprotection of Central Nervous System Cells against Oxidative Stress via the Nuclear Factor (Erythroid-Derived 2)-Like 2 Pathway. Journal of Pharmacology and Experimental Therapeutics, 341(1), 274–284. https://doi.org/10.1124/jpet.111.190132Stashenko, P., Nadler, L. E. E. M., Hardy, R., & Schlossman, S. F. (1980). Characterization of a human B lymphocyte-specific antigen. The Journal of Immunology, 125(4), 1678–1685.The IFNB Multiple Sclerosis Study Group. (1993). Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebocontrolled trial. The IFNB Multiple Sclerosis Study Group. Neurology, 43(4), 655–661.Thompson, A. J., Banwell, B. L., Barkhof, F., Carroll, W. M., Coetzee, T., Comi, G., … Cohen, J. A. (2018). Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. The Lancet Neurology, 17(2), 162–173. https://doi.org/10.1016/S1474-4422(17)30470- 2Tolley, K., Hutchinson, M., You, X., Wang, P., Sperling, B., Taneja, A., … Kinter, E. (2015). A network meta-analysis of efficacy and evaluation of safety of subcutaneous pegylated interferon beta-1a versus other injectable therapies for the treatment of relapsingremitting multiple sclerosis. PLoS ONE, 10(6), 1–21. https://doi.org/10.1371/journal.pone.0127960U.S Food and Drug Administration (FDA). (1993). BETASERON. Recuperado el 19 de febrero de 2019, de https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/1 03471s0000TOC.cfmU.S Food and Drug Administration (FDA). (1996a). AVONEX. Recuperado el 19 de febrero de 2019, de https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/1036 28s0000TOC.cfmU.S Food and Drug Administration (FDA). (1996b). COPAXONE. Recuperado el 19 de febrero de 2019, de https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?ev ent=overview.process&ApplNo=020622U.S Food and Drug Administration (FDA). (2001). ALEMTUZUMAB. Recuperado el 19 de febrero de 2019, de https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?ev ent=overview.process&ApplNo=103948U.S Food and Drug Administration (FDA). (2004). TYSABRI. Recuperado el 19 de febrero de 2019, de https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/12 5104s000_natalizumab.cfmU.S Food and Drug Administration (FDA). (2010). GYLENIA. Recuperado el 19 de febrero de 2019, de https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/02 2527Orig1s000TOC.cfmU.S Food and Drug Administration (FDA). (2012). AUBAGIO. Recuperado el 19 de febrero de 2019, de https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/20 2992Orig1s000TOC.cfmU.S Food and Drug Administration (FDA). (2013). TECFIDERA. Recuperado el 19 de febrero de 2019, de https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/20 4063orig1s000toc.cfmU.S Food and Drug Administration (FDA). (2017). OCREVUS. Recuperado el 19 de febrero de 2019, de https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/76 1053Orig1s000TOC.cfmVargas, D. L., & Tyor, W. R. (2017). Update on disease-modifying therapies for multiple sclerosis. Journal of Investigative Medicine, 65(5), 883– 891. https://doi.org/10.1136/jim-2016-000339Weideman, A. M., Tapia-Maltos, M. A., Johnson, K., Greenwood, M., & Bielekova, B. (2017). Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments. Frontiers in Neurology, 8(NOV), 1–12. https://doi.org/10.3389/fneur.2017.00577Xia, M. -Q, Tone, M., Packman, L., Hale, G., & Waldmann, H. (1991). Characterization of the CAMPATH-1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone. European Journal of Immunology, 21(7), 1677– 1684. https://doi.org/10.1002/eji.1830210714Yednock, T. A., Cannon, C., Fritz, L. C., Sanchez-Madrid, F., Steinman, L., & Karin, N. (1992). Prevention of experimental autoimmune encephalomyelitis by antibodies against α4βl integrin. Nature, 356(6364), 63–66. https://doi.org/10.1038/356063a0.Esclerosis múltipleEsclerosis múltiple crónica progresivaEsclerosis múltiple recurrente-remitenteTratamiento farmacológicoInmunosupresoresMultiple sclerosisChronic progressive multiple sclerosisRelapsing-remitting multiple sclerosisDrug therapyImmunosuppressive agentsMedicamentos modificadores en esclerosis múltiple: esquemas terapéuticos actualesArtículos Científicoshttp://purl.org/coar/resource_type/c_2df8fbb1http://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionAtribución – No comercial – Sin Derivarinfo:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2PublicationORIGINALMedicamentos modificadores en esclerosis múltiple esquemas terapéuticos actuales Rev. Chil. Neuropsicol. 15(1) 32-37, 2020.pdfMedicamentos modificadores en esclerosis múltiple esquemas terapéuticos actuales Rev. Chil. Neuropsicol. 15(1) 32-37, 2020.pdfArtículoapplication/pdf519558https://repository.ucc.edu.co/bitstreams/4da7324d-808a-494d-a89d-8a41497a40e7/download6404aafd01cfc8df5025809ac0f2de9dMD51LICENSElicense.txtlicense.txttext/plain; charset=utf-84334https://repository.ucc.edu.co/bitstreams/4542d997-51d1-45d1-bc8e-2c9981c9588c/download3bce4f7ab09dfc588f126e1e36e98a45MD52THUMBNAILMedicamentos modificadores en esclerosis múltiple esquemas terapéuticos actuales Rev. Chil. Neuropsicol. 15(1) 32-37, 2020.pdf.jpgMedicamentos modificadores en esclerosis múltiple esquemas terapéuticos actuales Rev. Chil. Neuropsicol. 15(1) 32-37, 2020.pdf.jpgGenerated Thumbnailimage/jpeg4932https://repository.ucc.edu.co/bitstreams/cfbd982a-b2e3-44ac-8e1e-d701ee1fe32c/download7409c6bae8b75db76e16be540d4a5af5MD53TEXTMedicamentos modificadores en esclerosis múltiple esquemas terapéuticos actuales Rev. Chil. Neuropsicol. 15(1) 32-37, 2020.pdf.txtMedicamentos modificadores en esclerosis múltiple esquemas terapéuticos actuales Rev. Chil. Neuropsicol. 15(1) 32-37, 2020.pdf.txtExtracted texttext/plain51035https://repository.ucc.edu.co/bitstreams/3f3816cd-eafa-4fe0-8de4-fdc2637d2b30/downloadeddb4ee08f2ef728fb5d03eb47533792MD5420.500.12494/33474oai:repository.ucc.edu.co:20.500.12494/334742024-08-10 22:49:44.232restrictedhttps://repository.ucc.edu.coRepositorio Institucional Universidad Cooperativa de Colombiabdigital@metabiblioteca.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

Publicaciones similares